BIOMAT Database Logo BIOMAT Database Logo

[Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy]. 2013

Merja Soilu-Hänninen, and Markku Päivärinta, and Pirkko Sonninen, and Riitta Parkkola, and Tytti Vuorinen, and Juha-Pekka Erälinna

Natalizumab medication used in the treatment of active relapsing-remitting multiple sclerosis is associated with a risk of contracting progressive multifocal leukoencephalopathy (PML). Current risk of the PML disease in connection with natalizumab therapy in multiple sclerosis patients is 2.77/1,000. By December 2012, more than 108,000 multiple sclerosis patients worldwide have received natalizumab therapy. There are 350 multiple sclerosis patients receiving natalizumab in Finland. We describe the first one of the two Finnish multiple sclerosis patients having so far been diagnosed with PML disease as a complication of natalizumab therapy.

UI MeSH Term Description Entries
D007968 Leukoencephalopathy, Progressive Multifocal An opportunistic viral infection of the central nervous system associated with conditions that impair cell-mediated immunity (e.g., ACQUIRED IMMUNODEFICIENCY SYNDROME and other IMMUNOLOGIC DEFICIENCY SYNDROMES; HEMATOLOGIC NEOPLASMS; IMMUNOSUPPRESSION; and COLLAGEN DISEASES). The causative organism is JC Polyomavirus (JC VIRUS) which primarily affects oligodendrocytes, resulting in multiple areas of demyelination. Clinical manifestations include DEMENTIA; ATAXIA; visual disturbances; and other focal neurologic deficits, generally progressing to a vegetative state within 6 months. (From Joynt, Clinical Neurology, 1996, Ch26, pp36-7) Encephalitis, JC Polyomavirus,Progressive Multifocal Leukoencephalopathy,JC Polyomavirus Encephalopathy,Encephalopathies, JC Polyomavirus,Encephalopathy, JC Polyomavirus,JC Polyomavirus Encephalitis,Leukoencephalopathies, Progressive Multifocal,Multifocal Leukoencephalopathies, Progressive,Multifocal Leukoencephalopathy, Progressive,Progressive Multifocal Leukoencephalopathies
D005387 Finland A country in northern Europe, bordering the Baltic Sea, Gulf of Bothnia, and Gulf of Finland, between Sweden and Russia. The capital is Helsinki. Aland Islands,Åland Islands
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069442 Natalizumab A humanized monoclonal immunoglobulin G4 antibody to human INTEGRIN ALPHA4 that binds to the alpha4 subunit of INTEGRIN ALPHA4BETA1 and integrin alpha4beta7. It is used as an IMMUNOLOGIC FACTOR in the treatment of RELAPSING-REMITTING MULTIPLE SCLEROSIS and CROHN'S DISEASE. Antegren,Tysabri
D012306 Risk The probability that an event will occur. It encompasses a variety of measures of the probability of a generally unfavorable outcome. Relative Risk,Relative Risks,Risk, Relative,Risks,Risks, Relative
D061067 Antibodies, Monoclonal, Humanized Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab. Antibodies, Humanized,Humanized Antibodies
D020529 Multiple Sclerosis, Relapsing-Remitting The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914) Multiple Sclerosis, Acute Relapsing,Relapsing-Remitting Multiple Sclerosis,Acute Relapsing Multiple Sclerosis,Remitting-Relapsing Multiple Sclerosis,Multiple Sclerosis, Relapsing Remitting,Multiple Sclerosis, Remitting-Relapsing,Relapsing Remitting Multiple Sclerosis,Remitting Relapsing Multiple Sclerosis

Related Publications

Merja Soilu-Hänninen, and Markku Päivärinta, and Pirkko Sonninen, and Riitta Parkkola, and Tytti Vuorinen, and Juha-Pekka Erälinna
[Progressive multifocal leukoencephalopathy after natalizumab therapy].
October 2005, Medecine sciences : M/S,
Merja Soilu-Hänninen, and Markku Päivärinta, and Pirkko Sonninen, and Riitta Parkkola, and Tytti Vuorinen, and Juha-Pekka Erälinna
Progressive multifocal leukoencephalopathy and natalizumab.
November 2011, Journal of neurology,
Merja Soilu-Hänninen, and Markku Päivärinta, and Pirkko Sonninen, and Riitta Parkkola, and Tytti Vuorinen, and Juha-Pekka Erälinna
Natalizumab-induced progressive multifocal leukoencephalopathy.
July 2014, Clinical nuclear medicine,
Merja Soilu-Hänninen, and Markku Päivärinta, and Pirkko Sonninen, and Riitta Parkkola, and Tytti Vuorinen, and Juha-Pekka Erälinna
Natalizumab-associated progressive multifocal leukoencephalopathy.
August 2012, The New England journal of medicine,
Merja Soilu-Hänninen, and Markku Päivärinta, and Pirkko Sonninen, and Riitta Parkkola, and Tytti Vuorinen, and Juha-Pekka Erälinna
Natalizumab-associated progressive multifocal leukoencephalopathy.
August 2012, The New England journal of medicine,
Merja Soilu-Hänninen, and Markku Päivärinta, and Pirkko Sonninen, and Riitta Parkkola, and Tytti Vuorinen, and Juha-Pekka Erälinna
Natalizumab and progressive multifocal leukoencephalopathy.
July 2005, The New England journal of medicine,
Merja Soilu-Hänninen, and Markku Päivärinta, and Pirkko Sonninen, and Riitta Parkkola, and Tytti Vuorinen, and Juha-Pekka Erälinna
Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
August 2006, Current opinion in neurology,
Merja Soilu-Hänninen, and Markku Päivärinta, and Pirkko Sonninen, and Riitta Parkkola, and Tytti Vuorinen, and Juha-Pekka Erälinna
Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
January 2014, Annals of neurology,
Merja Soilu-Hänninen, and Markku Päivärinta, and Pirkko Sonninen, and Riitta Parkkola, and Tytti Vuorinen, and Juha-Pekka Erälinna
Progressive multifocal leukoencephalopathy after natalizumab monotherapy.
September 2009, The New England journal of medicine,
Merja Soilu-Hänninen, and Markku Päivärinta, and Pirkko Sonninen, and Riitta Parkkola, and Tytti Vuorinen, and Juha-Pekka Erälinna
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.
July 2005, The New England journal of medicine,
Copied contents to your clipboard!